NTRK fusions: A novel diagnostic and therapeutic methodology for cancer

Abstract

This commentary discusses the case from the publication “Metastatic Triple Negative Breast Cancer with NTRK Gene Fusion on Tissue but not on ctDNA Molecular Profile.” This paper stresses the importance of molecular profiling to find characteristic mutations such as NTRK gene fusions which increase therapeutic options including tyrosine receptor kinase inhibitors such as Larotrectinib and entrectinib. The current profiling techniques are also discussed with both advantages and limitations discussed. Genomic testing in relation to current pharmaceutical therapies will shape the future of cancer diagnosis and treatment.